Resmed Q2 26 Earnings Conference Call At 4:30 PM ET

ResMed Inc. (RMD) will host a conference call at 4:30 PM ET on January 29, 2026 to discuss its fiscal Q2 2026 earnings results, with a live webcast at https://investor.resmed.com. A replay will be available by dialing +1 877.660.6853 (US) or +1 201.612.7415 (International) using Conference ID 13757750.

Analysis

Contrarian angles: Consensus overlooks margin upside from ResMed’s software and service tiers; a modest beat with raised software ARR guidance could unlock 8–15% upside within 1 month, a move markets may underprice pre-call. Conversely, a small miss could be over-sold — historically RMD recovers quickly from execution miscues, so buying dips below a -10% post-earnings drop has favorable risk/reward. Unintended consequence: aggressive shorting into earnings can spike IV and create cheap long-option entry post-crush, so prefer defined-risk option spreads to capture asymmetric outcomes.

Key Decisions for Investors

• Establish a 1–2% long position in RMD (ticker: RMD) ahead of the Jan 29 Q2 call; if EPS > consensus by ≥5% and revenue > consensus by ≥2% with raised guidance, increase to 3% and set a target +12% within 1 month, stop-loss at -6%.
• If expecting a large move, buy an ATM straddle in RMD with 7–10 day expiry (covering the Jan 29 event) only if total premium ≤2.5% of spot (implying a required move ~±6%); otherwise purchase a 90-day call spread (buy ATM, sell ATM+25%) sized to 0.5–1% portfolio to play upside while limiting premium outlay.
• Enter a relative-value pair: long RMD vs short Fisher & Paykel (FPH) in equal notional sizes for 0.5–1% net exposure to capture superior recurring revenue leverage; reassess after 3 months or on any CMS reimbursement draft within 30–60 days.
• Reallocate 1–2% from broad med-tech exposure (e.g., XLV/XLV alternatives) into RMD if the company reports ARR growth >10% YoY, otherwise keep exposure neutral; use covered calls (30–60 day) to harvest premium if holding through earnings, capping upside at +8–10%.